Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thank you for the feedback. Much appreciated. I see from BioNTech's own news flow that they seem very bullish about their strategy, although I do think it will be well into 2020 before we know if their individualised cancer vaccines are really the panacea. they hope for. Ugur Sahin remains very bullish about his Co. Of course the US Co. Genentech are also moving strongly in this area of expertise/development as well, but again nothing really conclusive yet as far as I can ascertain. Let's hope there is progress for cancer patients soon wherever it comes from. Making money must be second fiddle to that imo.
Bermuda, yes I do think of late you are being very pedantic. I don"t have an issue with that if I am providing wrong information, but i have two accounts so far, one from somebody who was there who said the BOD nodded in agreement and you saying you could audibly hear their confirmation.I am giving Vanvan a basic outline to a question he asked, this was additional opinion.
It follows on from a few interventions after posting CHs actual words in regard to Keith Flaherty, what better a way for those to draw there own conclusions and your suggestion was It was not conirmation that he would be trial investigator, but better than taking on board your doubts as to any involvement with him. Perhaps there could have been a misunderstanding had the posts not been read fully. I have nticed the same with a few of crumbs posts too, as if you are quelling any blatant ramping which doen"t exist but makes good reading for the posters who like to criticise what is not taking place.
I f you believe anyone is posting false information to encurage buying I would much prefer you guys answering questions than me having to justify posts where semantics are IMHO are running wild, and then spending time defending posts which are being singled out for unnecesary criticism.
So yes and it is not a big deal, I do believe you are being pedantic, and giving cause unneccasirily for some very patronising responses. One for you to look at Bermuda
Chelsea,
I know you may think I'm being pedantic, but think it's important to clarify again - Scancell confirmed at the AGM that they would issue an RNS when the first patient had been dosed. Once they have issued that RNS then we shouldn't expect any further updates until the last of the 6 safety run-in patients have been dosed.
So in short, we won't be told when each and every patient is enrolled and screened, just when the first and last patient has been dosed. Anything on top of that would be a bonus. This is entirely consistent with standard practice for AIM bios and indeed Scancell's previous SCIB1 trial.
Lol.
https://twitter.com/JIxn123/status/1196140081150644224
Someone has put a nice concise reply to that Dr Ursula thread. Have to say, for the time being, I agree with the sentiment.
On the Immunobody platform alome bews from CRUK as to timelines fror the SCIB2 trial will be welcome, and apparantly at the AGM whetherit would be by reaction or the spoken word Scancell confirmed they would be updating us for each patient screened and enrolled, in the absence of any updates we are led to presume no patients have been enrolled, something and IMHO I have trouble accepting. Positive info on either trial will be well received IMHO, and the price of no news has been seeing another 50% shaved off the share price which was 7.4p at the AGM to 5p now. A buying opportunity?? Well for each to decide but certainly good to see some PI buying at the end of last week, which will be well received if it continues tomorrow.
Evening VanVan, yes it is basically the same, just notification of having six posters on display at a Conference, and a new addition on the board.....................
Talent4Boards
@talent4boards
Scancell appoints Dr Ursula Ney to #BoardOfDirectors as NonExec Director
@scancellpharma
#WomenOnBoard $SCLP
Slow progress well it has been 9/10 weeks, certainly too slow for the demands of the AIM market, and with slow progress recruiting for the SCIB1/Keytruda trial the share has slipped further from 7.4p to 5p again the price Vulpes paid for their 16.67% stake some six months ago, when we rose nicely to just under 10p.
Updates on all platforms will be welcomed by us all, but rest assured we are all in the same position, volumes have been very low, with a buyer and a seller dominating, last Thursday and Friday we saw the first real signs of PI buying around 5.09. Take care
Can anyone comment on where we are with Modi 1 (TNBC trial) and our developing relationship with BioNTech?
Is it basically the same as reported at the AGM in September? Slow progress!